Activities
PMAC is committed to advancing cancer research through collaborative, multi-institutional efforts that generate robust, high-quality data. Our work is powered by a comprehensive, well-annotated database that integrates clinical, pathological, molecular, and treatment information, along with patient outcomes, to support precision medicine initiatives. Currently, this resource includes data from patients diagnosed with breast cancer who have undergone liquid biopsy testing.
The database continues to expand as new patients are enrolled across participating institutions, strengthening the foundation for impactful research.
PMAC’s scientific productivity is reflected in its consistent presence at major international conferences and numerous publications in high-impact, peer-reviewed journals. These contributions have significantly advanced the understanding of breast cancer biology, mechanisms of treatment resistance, and the clinical utility of liquid biopsy technologies.
PMAC at a Glance
11
Research Articles
12
Academic Institutions
3,000+
Database entries
Our Publications
_Page_01.jpg)
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis
Pontolillo et al., npj Breast Cancer
(2025)
Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer
Podany et al., JAMA Network Open
(2025)
Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor‑positive breast cancer and impact on clinical outcomes
Medford et al., Breast cancer research and treatment (2025)
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling
Gerratana et al., Cancer Letters
(2025)
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis
Gerratana et al., Breast Cancer Research
(2023)
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Hensing et al., Clinical Cancer Research
(2023)
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis
Gerratana et al., JCO precision oncology
(2023)
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer
Davis et al., EBioMedicine
(2022)
The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer
Jacob et al., Clinical Cancer Research
(2021)
Landscape of circulating tumour DNA in metastatic breast cancer
Davis et al., EBioMedicine
(2020)